APA (7th ed.) Citation

Kay, J., Jaworski, J., Wojciechowski, R., Wiland, P., Dudek, A., Krogulec, M., . . . Keystone, E. (2021). Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis research & therapy, 23(1), 51-12. https://doi.org/10.1186/s13075-020-02394-7

Chicago Style (17th ed.) Citation

Kay, Jonathan, et al. "Efficacy and Safety of Biosimilar CT-P17 Versus Reference Adalimumab in Subjects with Rheumatoid Arthritis: 24-week Results from a Randomized Study." Arthritis Research & Therapy 23, no. 1 (2021): 51-12. https://doi.org/10.1186/s13075-020-02394-7.

MLA (9th ed.) Citation

Kay, Jonathan, et al. "Efficacy and Safety of Biosimilar CT-P17 Versus Reference Adalimumab in Subjects with Rheumatoid Arthritis: 24-week Results from a Randomized Study." Arthritis Research & Therapy, vol. 23, no. 1, 2021, pp. 51-12, https://doi.org/10.1186/s13075-020-02394-7.